"HIV Protease Inhibitors" is a descriptor in the National Library of Medicine's controlled vocabulary thesaurus,
MeSH (Medical Subject Headings). Descriptors are arranged in a hierarchical structure,
which enables searching at various levels of specificity.
Inhibitors of HIV PROTEASE, an enzyme required for production of proteins needed for viral assembly.
Descriptor ID |
D017320
|
MeSH Number(s) |
D27.505.519.389.745.420 D27.505.954.122.388.077.088.420
|
Concept/Terms |
|
Below are MeSH descriptors whose meaning is more general than "HIV Protease Inhibitors".
Below are MeSH descriptors whose meaning is more specific than "HIV Protease Inhibitors".
This graph shows the total number of publications written about "HIV Protease Inhibitors" by people in this website by year, and whether "HIV Protease Inhibitors" was a major or minor topic of these publications.
To see the data from this visualization as text,
click here.
Year | Major Topic | Minor Topic | Total |
---|
1999 | 0 | 1 | 1 |
2000 | 1 | 2 | 3 |
2004 | 0 | 1 | 1 |
2005 | 0 | 1 | 1 |
2007 | 2 | 2 | 4 |
2008 | 1 | 0 | 1 |
2009 | 2 | 0 | 2 |
2010 | 1 | 0 | 1 |
2012 | 2 | 0 | 2 |
2013 | 2 | 0 | 2 |
2014 | 1 | 0 | 1 |
2015 | 1 | 0 | 1 |
2016 | 0 | 1 | 1 |
To return to the timeline,
click here.
Below are the most recent publications written about "HIV Protease Inhibitors" by people in Profiles.
-
Integrase inhibitors in late pregnancy and rapid HIV viral load reduction. Am J Obstet Gynecol. 2016 Mar; 214(3):385.e1-7.
-
Pharmacokinetics of tenofovir during pregnancy and postpartum. HIV Med. 2015 Sep; 16(8):502-11.
-
Cost-minimization comparison of darunavir plus ritonavir and lopinavir/ritonavir in HIV-1 infected treatment-na?ve women of childbearing age. J Med Econ. 2014 Apr; 17(4):250-8.
-
P1 and P1' para-fluoro phenyl groups show enhanced binding and favorable predicted pharmacological properties: structure-based virtual screening of extended lopinavir analogs against multi-drug resistant HIV-1 protease. J Mol Graph Model. 2014 Feb; 47:18-24.
-
Ligand modifications to reduce the relative resistance of multi-drug resistant HIV-1 protease. Bioorg Med Chem. 2013 Dec 01; 21(23):7430-4.
-
Economic and health-related quality-of-life (HRQoL) comparison of lopinavir/ritonavir (LPV/r) and atazanavir plus ritonavir (ATV+RTV) based regimens for antiretroviral therapy (ART)-na?ve and -experienced United Kingdom patients in 2011. J Med Econ. 2012; 15(4):796-806.
-
Crystal structures of multidrug-resistant HIV-1 protease in complex with two potent anti-malarial compounds. Biochem Biophys Res Commun. 2012 May 11; 421(3):413-7.
-
Broadening the perspective when assessing evidence on boosted protease inhibitor-based regimens for initial antiretroviral therapy. Adv Ther. 2010 Nov; 27(11):763-73.
-
Report from the 5th IAS Conference on HIV Pathogenesis Treatment and Prevention. ALTAIR--the end of NRTI-only regimes. J Watch AIDS Clin Care. 2009 Oct; 21(10):82.
-
Comparison of Markov model and discrete-event simulation techniques for HIV. Pharmacoeconomics. 2009; 27(2):159-65.